p38 MAPK (mitogen-activated protein kinase 14) is a family of serine/threonine protein kinases activated by cellular stress, inflammatory cytokines, and environmental insults. The p38 family comprises four isoforms: p38α (MAPK14), p38β (MAPK11), p38γ (MAPK12), and p38δ (MAPK13). In the brain, p38α is the predominant isoform expressed in neurons, microglia, and astrocytes. p38 is centrally implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders through its regulation of neuroinflammation, tau phosphorylation, and neuronal apoptosis. [1]
| Property | Value |
|---|---|
| Gene Symbols | MAPK14 (p38α), MAPK11 (p38β), MAPK12 (p38γ), MAPK13 (p38δ) |
| Chromosomal Location | MAPK14: 6p21.31, MAPK11: 22q13.13, MAPK12: 15q21.2, MAPK13: 6p21.31 |
| UniProt IDs | Q16539 (p38α), P53778 (p38β), P53779 (p38γ), O15264 (p38δ) |
| Molecular Weight | ~38-40 kDa per isoform |
| Brain Expression | p38α: ubiquitous in neurons, microglia, astrocytes; p38β: lower expression; p38γ/p38δ: restricted |
p38 MAPK adopts a typical bilobal kinase structure with an N-terminal activation segment containing the Thr-Gly-Tyr (TGY) dual phosphorylation motif. Activation requires phosphorylation of both Thr180 and Tyr182 by upstream MAPKKs (MKK3 and MKK6). The kinase contains a docking domain for interaction with substrates and regulators. p38α, the primary brain isoform, is a 360-amino acid protein that forms dimers upon activation, which is required for full kinase activity. [@falgicchia2020]
p38 is activated through a canonical kinase cascade:
| Substrate | Function | Role in Neurodegeneration |
|---|---|---|
| ATF2 | Transcription factor | Pro-inflammatory gene expression |
| CHOP (DDIT3) | Transcription factor | Pro-apoptotic, ER stress |
| MAPKAPK2/3 | Kinase | Tau phosphorylation, cytokine production |
| Tau (MAPT) | Cytoskeletal protein | Multiple pathological sites |
| MSK1/2 | Kinase | Histone phosphorylation, gene expression |
| Hsp27 | Chaperone | Cytoskeletal stability |
In the healthy brain, p38 regulates:
p38 is strongly activated in Alzheimer's disease brain tissue, particularly in microglia surrounding amyloid plaques and in vulnerable neurons. [2]
p38 is the master regulator of pro-inflammatory cytokine production in microglia:
Selective p38α/β inhibition with compounds like neflamapimod (PH-797804 derivative) reduces microglial activation and improves cognitive function in 5XFAD mouse models. [2:1]
p38 directly phosphorylates tau at multiple disease-relevant sites:
Aβ oligomers activate p38 through multiple mechanisms:
p38 activation in synapses contributes to:
p38 inhibition reverses Aβ-induced synaptic dysfunction and improves spatial memory in animal models. [@falgicchia2020]
Neflamapimod (a p38α-selective inhibitor) has been tested in clinical trials for AD:
Losmapimod has also been investigated for its effects on neuroinflammation and cognitive function in AD. [3]
In Parkinson's disease, p38 drives neuroinflammation and dopaminergic neuron death:
α-Synuclein aggregates activate p38:
| Compound | Selectivity | Development Stage |
|---|---|---|
| SB203580 | Broad p38 inhibitor | Preclinical tool compound |
| PH-797804 | Selective p38 inhibitor | Preclinical |
| Losmapimod | p38α/β inhibitor | Phase 2 (AD, COPD) |
| Neflamapimod (VX-745) | Selective p38α | Phase 2 (AD) |
| Pamapimod | p38 inhibitor | Phase 2 (RA, psoriasis) |
| Partner | Interaction Type | Function |
|---|---|---|
| MKK3 | Phosphorylation | Primary p38α activator |
| MKK6 | Phosphorylation | Alternative p38α activator |
| ATF2 | Phosphorylation | Transcription factor activation |
| CHOP (DDIT3) | Phosphorylation | ER stress, apoptosis |
| MAPKAPK2 | Phosphorylation | Cytokine production, tau phosphorylation |
| Tau (MAPT) | Phosphorylation | Cytoskeletal dysregulation |
| Hsp27 | Phosphorylation | Cytoskeletal protection |
| MSK1/2 | Phosphorylation | Chromatin remodeling |
Corr理解和描述. et al. p38 MAPK in neuroinflammation and neurodegeneration. Cellular and Molecular Life Sciences. 2021. ↩︎
Gee MS, et al. A selective p38alpha/beta MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse. Acta Neuropathologica Communications. 2020. ↩︎ ↩︎
Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. 2022. ↩︎